{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:07:20Z","timestamp":1771376840374,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2025.10.017","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:39:08Z","timestamp":1761413948000},"page":"169.e1-169.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study"],"prefix":"10.1016","volume":"32","author":[{"given":"Marta","family":"Pe\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Fernando","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana \u00c1frica","family":"Mart\u00edn-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Sanchez-Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-0831","authenticated-orcid":false,"given":"Ana","family":"Benzaqu\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aitana","family":"Balaguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-9195","authenticated-orcid":false,"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Filaferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascual","family":"Balsalobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Barba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jtct.2025.10.017_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.017_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.017_bib0003","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.017_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.017_bib0005","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.017_bib0006","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.jtct.2025.10.017_bib0007","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.017_bib0008","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR t-cell therapy in patients with b-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.jtct.2025.10.017_bib0009","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.017_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.017_bib0011","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.017_bib0012","first-page":"195","article-title":"Predicting outcomes following anti-CD19 car T cell therapy in aggressive B cell lymphomas","volume":"27","author":"Ho","year":"2021","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.017_bib0013","doi-asserted-by":"crossref","first-page":"187.e1","DOI":"10.1016\/j.jtct.2023.11.016","article-title":"Easix score correlates with endothelial dysfunction biomarkers and predicts risk of acute graft-versus-host disease after allogeneic transplantation","volume":"30","author":"Pedraza","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.017_bib0014","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","article-title":"EASIX and mortality after allogeneic stem cell transplantation","volume":"55","author":"Luft","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.017_bib0015","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.017_bib0016","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3324\/haematol.2019.238790","article-title":"Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel","volume":"106","author":"Jiang","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.017_bib0017","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2020.01.028","article-title":"Endothelial activation and stress index (EASIX) at admission predicts fluid overload in recipients of allogeneic stem cell transplantation","volume":"26","author":"Varma","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jtct.2025.10.017_bib0018","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/bloodadvances.2021004812","article-title":"Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation","volume":"5","author":"Pe\u00f1a","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.017_bib0019","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41409-023-01922-8","article-title":"EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation","volume":"58","author":"Sanchez-Escamilla","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jtct.2025.10.017_bib0020","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.017_bib0021","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.017_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-022-00777-4","article-title":"Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma","volume":"13","author":"Acosta-Medina","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2024.100025","article-title":"EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy","volume":"1","author":"Gavriilaki","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"3.5","key":"10.1016\/j.jtct.2025.10.017_bib0024","doi-asserted-by":"crossref","first-page":"CLO25","DOI":"10.6004\/jnccn.2024.7218","article-title":"CLO25-089: the prognostic value of the Endothelial Activation and Stress Index (EASIX) in predicting clinical and survival outcomes and treatment response for patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy","volume":"23","author":"Vashisht","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.017_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.017_bib0026","doi-asserted-by":"crossref","first-page":"e1460","DOI":"10.1002\/wics.1460","article-title":"The Akaike information criterion: Background, derivation, properties, application, interpretation, and refinements","volume":"11","author":"Cavanaugh","year":"2019","journal-title":"WIREs Comput Stat"},{"issue":"22","key":"10.1016\/j.jtct.2025.10.017_bib0027","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.017_bib0028","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.jtct.2025.10.017_bib0029","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2025.10.017_bib0030","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:23:01Z","timestamp":1771374181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666636725015192"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}